Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Non-Celiac Wheat Sensitivity Is an Immune Disorder, Too

Andrew M. Seaman  |  August 3, 2016

(Reuters Health)—People who feel ill after eating wheat, but who don’t have celiac disease, may finally have a biological explanation for their symptoms, a new study suggests. Researchers from the U.S. and Italy found that people who claim to have wheat sensitivity do have biological reactions to gluten proteins in wheat, rye and barley. It’s…

New RA Therapy Promising in Clinical Trial

Michele B. Kaufman, PharmD, BCGP  |  August 3, 2016

Results from a clinical trial support the efficacy of vobarilizumab for treating RA. Plus, the UK will recommend the use of certolizumab pegol to treat severe cases of RA in upcoming guidelines…

Milestones of Rheumatology Education

Arthritis Care & Research  |  August 2, 2016

In 2013, a collaboration began to advance the training and assessment of fellows. The result: A uniform set of educational reporting milestones for all internal medicine subspecialties was developed. Key stakeholders were then asked to develop a list of entrustable professional activities (EPAs), a set of responsibilities any specialist should be able to perform, for their subspecialties. The ACR’s Next Accreditation System working group developed 14 EPAs for rheumatology…

Methotrexate with Step-Down Glucocorticoid Remission Induction Works in Early RA

Reuters Staff  |  August 1, 2016

NEW YORK (Reuters Health)—Methotrexate with step-down glucocorticoid remission induction (COBRA Slim) is an effective, safe and feasible initial treatment strategy for patients with early rheumatoid arthritis (RA), researchers from Belgium report. Patients with early RA should be treated rapidly, intensively and to target, according to current guidelines, they note in a paper online July 18…

Ultrasound May Be Useful for Grading Rotator Cuff Tendinopathy

Lara C. Pullen, PhD  |  August 1, 2016

Researchers have developed procedures and assessed their efficacy for the use of ultrasound images to measure the inter-rater reliability of the measurement of structural changes in the tendon of patients with supraspinatus tendinopathy. The standardized procedures proved useful in evaluating patients…

From the Expert: Musculoskeletal Ultrasound Training Benefits Rheumatology Practices & Patients

Richard Quinn  |  July 29, 2016

Eugene Kissin, MD, says the use of musculoskeletal ultrasound can help rheumatologists diagnose and treat disease. Getting the proper training is critical. USSONAR is a training resource that can help…

Secukinumab Inhibits Structural Joint Damage in Active PsA

Arthritis & Rheumatology  |  July 27, 2016

Psoriatic arthritis (PsA), a chronic inflammatory arthritis characterized by structural damage to the joints, has been associated with reduced health-related quality of life, disability and reduced life expectancy. The joint changes in PsA are characterized radiographically by a combination of erosive and proliferative bone changes, including erosive joint destruction, fluffy periostitis and pencil-in-cup deformities. Radiographic…

New FDA Warnings: Patients on SGLT2 Inhibitors at Risk of Acute Kidney Injury & Loperamide Abuse on the Rise

Michele B. Kaufman, PharmD, BCGP  |  July 27, 2016

The FDA is strengthening its warning that canagliflozin and dapagliflozin may increase the risk for acute kidney injury in some patients. Also, the FDA has issued a warning that patients should not exceed recommended doses of loperamide due to increased risks of serious cardiac events…

Healthy Clones: Dolly the Sheep’s Heirs Reach Ripe Old Age

Ben Hirschler  |  July 26, 2016

LONDON (Reuters)—The heirs of Dolly the sheep are enjoying a healthy old age, proving cloned animals can live normal lives and offering reassurance to scientists hoping to use cloned cells in medicine. Dolly, cloning’s poster child, was born in Scotland in 1996. She died prematurely in 2003, at age 6, after developing osteoarthritis and a…

EMA Flags Faulty Generic Drug Data, Backs Sales Halt

Reuters Staff  |  July 26, 2016

(Reuters)—The European Medicines Agency (EMA) recommended suspending sales of some generic drugs after a review found that data collected by a contract research company in India for their approval was unreliable. The EMA’s list included drugs made by some of the top generic drugmakers, including Teva Pharmaceutical Industries Ltd., Mylan NV and Novartis AG’s Sandoz….

  • « Previous Page
  • 1
  • …
  • 242
  • 243
  • 244
  • 245
  • 246
  • …
  • 317
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences